Navigation Links
Helix Bioscience Appointed DNA Drug Sensitivity Testing Distributor for Genelex Corporation
Date:7/14/2010

SEATTLE and TULSA, Okla., July 14 /PRNewswire/ -- Genelex and Helix have announced a personalized prescribing strategic alliance to increase the availability of important new DNA Drug Sensitivity Tests such as Plavitest™ and Tamoxitest™. These tests and the GeneMedRx medication management software can save lives and healthcare dollars by allowing doctors to personalize their prescribing practices in order to prevent adverse medication outcomes, including treatment failures and dangerous side effects.

"Helix's knowledge and experience make them ideally suited to expand access to these products and contribute to improving prescribing safety," said Howard Coleman, Genelex Chief Executive Officer.

Helix is concentrating its initial efforts on Plavitest™ due to the recent FDA boxed warning placed on Plavix. Recent clinical research demonstrates that approximately one-third of patients are in varying degrees of treatment failure and could be at an increased risk of a recurrent heart attack, stroke or cardiovascular death. Plavitest identifies these patients so doctors can improve their medication regimen and chances for successful treatment. Plavix is the second leading selling prescription drug with over $8 billion in worldwide annual sales.

"We chose Genelex as our laboratory partner because of its proven track record in delivering DNA Drug Sensitivity Tests and the advantage of the GeneMedRx interpretive software," said Lincoln Maxwell, Helix chief executive officer. GeneMedRx closes the "interpretation gap" by providing prescribers actionable information to reduce the risk of treatment failures and adverse reactions based on the genetics and overall medication regimen of patients.

Helix Biosciences is a new company formed by a team of diagnostic industry professionals to bring the benefits of genetic testing to doctors and their patients.

Genelex (jen-uh-LEX) sells a combination of DNA Drug Sensitivity Testing and the GeneMedRx (jeen-med-r-x) software to doctors to help them choose the safest, most effective medicines for their patients. Wide adoption of these technologies is aimed at dramatically reduce deaths and injuries from adverse drug reactions, interactions and treatment failure.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Howard Coleman

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=44528


'/>"/>
SOURCE Genelex
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Helix BioPharma Reports On 2009 Annual General Meeting
2. Helix BioPharma Corp. Announces Fiscal Q1 2010 Results
3. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
4. Helix BioPharma Corp. Announces Fiscal 2009 Results
5. Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
6. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
7. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
8. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
9. SeqWrights Partnership with EraGen Biosciences Contributes to FDA Market Clearance Success
10. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
11. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... NEW YORK , April 28, 2016 ... of online consumer insights on healthcare, announced today that ... in their report Cool Vendor in Life Sciences, ... , April 15, 2016.  The report focuses on life-science- ... to gain insight from patients and doctors, confirm medication ...
(Date:4/28/2016)... April 28, 2016   Acsis , a leading ... leading IT market research and advisory firm IDC has ... IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software 2016 ... provides an assessment of the capabilities and business strategies ... software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)...  Hologic, Inc. (Nasdaq: HOLX ) ... fiscal second quarter ended March 26, 2016.  GAAP ... 41.2%, and non-GAAP diluted EPS of $0.47 increased ... a reported basis, and 6.3% on a constant ... good quarter, highlighted by 14.6% growth in non-GAAP ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... The American ... productivity, stability, even security. Most importantly, employees are the single most important asset ... American workers so unhappy? , Just under half of American workers are emotionally ...
(Date:4/29/2016)... GA (PRWEB) , ... April 29, 2016 , ... Coast ... May 16, 2016, at its new location in the Exchange Furniture Mall at 112 ... raffle for a 50-inch Samsung Smart TV. Plus attendees will have the opportunity to ...
(Date:4/29/2016)... City, Missouri (PRWEB) , ... April 29, 2016 , ... ... traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes body ... strain on their wrists and hands when using the crutches than with other crutches. ...
(Date:4/29/2016)... CA (PRWEB) , ... April 29, 2016 , ... Dr. ... cosmetic dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as more ... This offer allows patients to learn more about the options currently available to them ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
Breaking Medicine News(10 mins):